Barbara J. Brennan

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

Franck Morschhauser, Paula Marlton, Umberto Vitolo et al. · Annals of Oncology · 2010 · 144 citations · Full text

Medicine, Hematology, Pharmacology +15

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Marwan Fakih, Kanwal Pratap Singh Raghav, David Chang et al. · EClinicalMedicine · 2023 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

Edward Gane, S. Roberts, Catherine Stedman et al. · Journal of Hepatology · 2009 · 63 citations

Medicine, Infectious Diseases, Pharmacology +14

Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate

Peter N. Morcos, Sebastian Moreira, Barbara J. Brennan et al. · European Journal of Clinical Pharmacology · 2013 · 43 citations

Medicine, Pharmacokinetics, Pharmacology +16

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Michael Dickinson, Javier Briones, Alex F. Herrera et al. · Blood Advances · 2021 · 36 citations · Full text

Medicine, Oncology, Pharmacotherapy +16